SCHEMBL4852309

SCHEMBL4852309

CCOP(=O)(CCc1cn(-c2ccccc2)nc1O)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
HPGD P15428 2/20 0.38
USP2 O75604 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
MAPK1 P28482 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
AURKA O14965 1/20 0.36
DGAT1 O75907 2/20 0.36
PTGES O14684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23401521 0.78 KDM4E (0.47) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL23403486 0.78 KDM4E (0.50) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL5113183 0.76 NPC1 (0.54) RAB9ANPC1ALDH1A1KDM4ENPSR1
SCHEMBL23399935 0.76 KDM4E (0.45) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL4843945 0.74 PDE4D (0.39) ALDH1A1KDM4EMAPTGAAL3MBTL1
SCHEMBL5415068 0.69 ALDH1A1 (0.49) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL5407279 0.69 KDM4E (0.68) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL27983648 0.69 FOLH1 (0.50) MAPTPOLBHTTMAPK1
SCHEMBL5248630 0.68 CETP (0.47) POLBNPSR1
SCHEMBL23398761 0.68 KDM4E (0.46) RAB9ANPC1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 RAB9A 1036/4885NPC1 822/4885ALDH1A1 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.